Cancer Therapeutics and Biotherapeutics

Cancer Therapeutics and Biotherapeutics Comprehensive Study by Type (Chemotherapy, Radiation Therapy, Hormone Therapy, Biotherapy), Application (Household, Hospital, Others), Therapy Type (Monoclonal Antibodies, Vaccines, Cell Therapy, Gene Therapy, Others), Cancer Type (Blood Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others), Treatment Drug (Nivolumab, Ipilimumab, Luspatercept, Ramucirumab, Others) Players and Region - Global Market Outlook to 2030

Cancer Therapeutics and Biotherapeutics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Cancer Therapeutics and Biotherapeutics
Biotherapeutics are “antibody-drug cell therapy products where the active substance is extracted or produced from a biological source.” Biotherapeutic products include proteins and hormones, monoclonal antibodies, cytokines, antibodies, gene cell therapy products, vaccines, stem cell therapies, and more. Many biotherapeutic molecules are considered a rapidly growing drug class for anti-immunity, oncology, and inflammatory diseases. Furthermore, the expanding elderly population is helping to expand and develop the global cancer therapeutics biotherapeutics market. The elderly are especially vulnerable to such diseases and require special attention and treatment.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Competition among existing players is due to the Cancer Therapeutics and Biotherapeutics market share occupied by leading players. The industry leader is engaged in offering innovative and superior quality products to cater to the ever-growing demand for Cancer Therapeutics and Biotherapeutics Market. The companies are implementing strategic activities such as acquisitions and mergers along with collaboration with companies in other industries to aid them in improving sustenance and maintaining their competitive advantage. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Cancer Therapeutics and Biotherapeutics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AstraZeneca (United Kingdom), Bristol-Myers Squibb (United States), Eli Lilly & Company (United States), Johnson & Johnson (United States), Merck (Germany), Novartis (Switzerland), Pfizer (United States), Roche (Switzerland), Sanofi (France), Biogen IDEC (United States) and Genentech (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Amgen Inc. (United States), Celgene Corporation (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Cancer Therapeutics and Biotherapeutics market by Type (Chemotherapy, Radiation Therapy, Hormone Therapy and Biotherapy), Application (Household, Hospital and Others) and Region.



On the basis of geography, the market of Cancer Therapeutics and Biotherapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Therapy Type, the sub-segment i.e. Monoclonal Antibodies will boost the Cancer Therapeutics and Biotherapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Cancer Type, the sub-segment i.e. Blood Cancer will boost the Cancer Therapeutics and Biotherapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Drug, the sub-segment i.e. Nivolumab will boost the Cancer Therapeutics and Biotherapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The increasing focus on targeted therapies and precision medicine.

Market Growth Drivers:
Technical improvements in cancer research and treatment., Increased use of Bio Pharmaceuticals in the treatment of various cancers such as breast, lung, and prostate cancer. and Surge in geriatric population.

Challenges:
High treatment cost.

Restraints:
Stringent regulatory requirement.

Opportunities:
Technological advancement such as AI and ML.

Market Leaders and their expansionary development strategies
In September 2020, Gilead Sciences announced the acquisition of Immunomedics, a clinical-stage biotechnology company focused on developing innovative cancer therapies. The acquisition was aimed at expanding Gilead's oncology portfolio and advancing its mission of improving the lives of patients with cancer.
In March 2024, Oxford Biotherapeutics, a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, announced significant technological advances to its drug discovery platform OGAP® with a new version to be launched at the 14th Annual World ADC Conference in London named OGAP®-Verify. OBT will also present two posters focusing on OGAP-Verifies capacity to identify novel cancer-specific targets for the development of first-in-class therapies, particularly ADCs and other therapeutic antibodies, addressing unmet clinical needs in oncology.


Key Target Audience
Manufacturers Suppliers and Distributors, Venture Capitalists and Private Equity Firms, New Entrants/Investors, Strategic Business Planners, Government Regulatory, Research Organizations, End-Use Industries and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Chemotherapy
  • Radiation Therapy
  • Hormone Therapy
  • Biotherapy
By Application
  • Household
  • Hospital
  • Others
By Therapy Type
  • Monoclonal Antibodies
  • Vaccines
  • Cell Therapy
  • Gene Therapy
  • Others

By Cancer Type
  • Blood Cancer
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others

By Treatment Drug
  • Nivolumab
  • Ipilimumab
  • Luspatercept
  • Ramucirumab
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Technical improvements in cancer research and treatment.
      • 3.2.2. Increased use of Bio Pharmaceuticals in the treatment of various cancers such as breast, lung, and prostate cancer.
      • 3.2.3. Surge in geriatric population.
    • 3.3. Market Challenges
      • 3.3.1. High treatment cost.
    • 3.4. Market Trends
      • 3.4.1. The increasing focus on targeted therapies and precision medicine.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Therapeutics and Biotherapeutics, by Type, Application, Therapy Type, Cancer Type, Treatment Drug and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Cancer Therapeutics and Biotherapeutics (Value)
      • 5.2.1. Global Cancer Therapeutics and Biotherapeutics by: Type (Value)
        • 5.2.1.1. Chemotherapy
        • 5.2.1.2. Radiation Therapy
        • 5.2.1.3. Hormone Therapy
        • 5.2.1.4. Biotherapy
      • 5.2.2. Global Cancer Therapeutics and Biotherapeutics by: Application (Value)
        • 5.2.2.1. Household
        • 5.2.2.2. Hospital
        • 5.2.2.3. Others
      • 5.2.3. Global Cancer Therapeutics and Biotherapeutics by: Therapy Type (Value)
        • 5.2.3.1. Monoclonal Antibodies
        • 5.2.3.2. Vaccines
        • 5.2.3.3. Cell Therapy
        • 5.2.3.4. Gene Therapy
        • 5.2.3.5. Others
      • 5.2.4. Global Cancer Therapeutics and Biotherapeutics by: Cancer Type (Value)
        • 5.2.4.1. Blood Cancer
        • 5.2.4.2. Breast Cancer
        • 5.2.4.3. Lung Cancer
        • 5.2.4.4. Colorectal Cancer
        • 5.2.4.5. Prostate Cancer
        • 5.2.4.6. Others
      • 5.2.5. Global Cancer Therapeutics and Biotherapeutics by: Treatment Drug (Value)
        • 5.2.5.1. Nivolumab
        • 5.2.5.2. Ipilimumab
        • 5.2.5.3. Luspatercept
        • 5.2.5.4. Ramucirumab
        • 5.2.5.5. Others
      • 5.2.6. Global Cancer Therapeutics and Biotherapeutics Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Cancer Therapeutics and Biotherapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly & Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Roche (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Biogen IDEC (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Genentech (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Cancer Therapeutics and Biotherapeutics Sale, by Type, Application, Therapy Type, Cancer Type, Treatment Drug and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Cancer Therapeutics and Biotherapeutics (Value)
      • 7.2.1. Global Cancer Therapeutics and Biotherapeutics by: Type (Value)
        • 7.2.1.1. Chemotherapy
        • 7.2.1.2. Radiation Therapy
        • 7.2.1.3. Hormone Therapy
        • 7.2.1.4. Biotherapy
      • 7.2.2. Global Cancer Therapeutics and Biotherapeutics by: Application (Value)
        • 7.2.2.1. Household
        • 7.2.2.2. Hospital
        • 7.2.2.3. Others
      • 7.2.3. Global Cancer Therapeutics and Biotherapeutics by: Therapy Type (Value)
        • 7.2.3.1. Monoclonal Antibodies
        • 7.2.3.2. Vaccines
        • 7.2.3.3. Cell Therapy
        • 7.2.3.4. Gene Therapy
        • 7.2.3.5. Others
      • 7.2.4. Global Cancer Therapeutics and Biotherapeutics by: Cancer Type (Value)
        • 7.2.4.1. Blood Cancer
        • 7.2.4.2. Breast Cancer
        • 7.2.4.3. Lung Cancer
        • 7.2.4.4. Colorectal Cancer
        • 7.2.4.5. Prostate Cancer
        • 7.2.4.6. Others
      • 7.2.5. Global Cancer Therapeutics and Biotherapeutics by: Treatment Drug (Value)
        • 7.2.5.1. Nivolumab
        • 7.2.5.2. Ipilimumab
        • 7.2.5.3. Luspatercept
        • 7.2.5.4. Ramucirumab
        • 7.2.5.5. Others
      • 7.2.6. Global Cancer Therapeutics and Biotherapeutics Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Therapeutics and Biotherapeutics: by Type(USD Million)
  • Table 2. Cancer Therapeutics and Biotherapeutics Chemotherapy , by Region USD Million (2018-2023)
  • Table 3. Cancer Therapeutics and Biotherapeutics Radiation Therapy , by Region USD Million (2018-2023)
  • Table 4. Cancer Therapeutics and Biotherapeutics Hormone Therapy , by Region USD Million (2018-2023)
  • Table 5. Cancer Therapeutics and Biotherapeutics Biotherapy , by Region USD Million (2018-2023)
  • Table 6. Cancer Therapeutics and Biotherapeutics: by Application(USD Million)
  • Table 7. Cancer Therapeutics and Biotherapeutics Household , by Region USD Million (2018-2023)
  • Table 8. Cancer Therapeutics and Biotherapeutics Hospital , by Region USD Million (2018-2023)
  • Table 9. Cancer Therapeutics and Biotherapeutics Others , by Region USD Million (2018-2023)
  • Table 10. Cancer Therapeutics and Biotherapeutics: by Therapy Type(USD Million)
  • Table 11. Cancer Therapeutics and Biotherapeutics Monoclonal Antibodies , by Region USD Million (2018-2023)
  • Table 12. Cancer Therapeutics and Biotherapeutics Vaccines , by Region USD Million (2018-2023)
  • Table 13. Cancer Therapeutics and Biotherapeutics Cell Therapy , by Region USD Million (2018-2023)
  • Table 14. Cancer Therapeutics and Biotherapeutics Gene Therapy , by Region USD Million (2018-2023)
  • Table 15. Cancer Therapeutics and Biotherapeutics Others , by Region USD Million (2018-2023)
  • Table 16. Cancer Therapeutics and Biotherapeutics: by Cancer Type(USD Million)
  • Table 17. Cancer Therapeutics and Biotherapeutics Blood Cancer , by Region USD Million (2018-2023)
  • Table 18. Cancer Therapeutics and Biotherapeutics Breast Cancer , by Region USD Million (2018-2023)
  • Table 19. Cancer Therapeutics and Biotherapeutics Lung Cancer , by Region USD Million (2018-2023)
  • Table 20. Cancer Therapeutics and Biotherapeutics Colorectal Cancer , by Region USD Million (2018-2023)
  • Table 21. Cancer Therapeutics and Biotherapeutics Prostate Cancer , by Region USD Million (2018-2023)
  • Table 22. Cancer Therapeutics and Biotherapeutics Others , by Region USD Million (2018-2023)
  • Table 23. Cancer Therapeutics and Biotherapeutics: by Treatment Drug(USD Million)
  • Table 24. Cancer Therapeutics and Biotherapeutics Nivolumab , by Region USD Million (2018-2023)
  • Table 25. Cancer Therapeutics and Biotherapeutics Ipilimumab , by Region USD Million (2018-2023)
  • Table 26. Cancer Therapeutics and Biotherapeutics Luspatercept , by Region USD Million (2018-2023)
  • Table 27. Cancer Therapeutics and Biotherapeutics Ramucirumab , by Region USD Million (2018-2023)
  • Table 28. Cancer Therapeutics and Biotherapeutics Others , by Region USD Million (2018-2023)
  • Table 29. South America Cancer Therapeutics and Biotherapeutics, by Country USD Million (2018-2023)
  • Table 30. South America Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 31. South America Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 32. South America Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 33. South America Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 34. South America Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 35. Brazil Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 36. Brazil Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 37. Brazil Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 38. Brazil Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 39. Brazil Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 40. Argentina Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 41. Argentina Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 42. Argentina Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 43. Argentina Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 44. Argentina Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 45. Rest of South America Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 46. Rest of South America Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 47. Rest of South America Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 48. Rest of South America Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 49. Rest of South America Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 50. Asia Pacific Cancer Therapeutics and Biotherapeutics, by Country USD Million (2018-2023)
  • Table 51. Asia Pacific Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 52. Asia Pacific Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 53. Asia Pacific Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 54. Asia Pacific Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 55. Asia Pacific Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 56. China Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 57. China Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 58. China Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 59. China Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 60. China Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 61. Japan Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 62. Japan Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 63. Japan Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 64. Japan Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 65. Japan Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 66. India Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 67. India Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 68. India Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 69. India Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 70. India Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 71. South Korea Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 72. South Korea Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 73. South Korea Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 74. South Korea Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 75. South Korea Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 76. Taiwan Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 77. Taiwan Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 78. Taiwan Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 79. Taiwan Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 80. Taiwan Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 81. Australia Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 82. Australia Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 83. Australia Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 84. Australia Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 85. Australia Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 86. Rest of Asia-Pacific Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 87. Rest of Asia-Pacific Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 88. Rest of Asia-Pacific Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 89. Rest of Asia-Pacific Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 90. Rest of Asia-Pacific Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 91. Europe Cancer Therapeutics and Biotherapeutics, by Country USD Million (2018-2023)
  • Table 92. Europe Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 93. Europe Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 94. Europe Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 95. Europe Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 96. Europe Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 97. Germany Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 98. Germany Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 99. Germany Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 100. Germany Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 101. Germany Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 102. France Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 103. France Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 104. France Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 105. France Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 106. France Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 107. Italy Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 108. Italy Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 109. Italy Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 110. Italy Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 111. Italy Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 112. United Kingdom Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 113. United Kingdom Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 114. United Kingdom Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 115. United Kingdom Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 116. United Kingdom Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 117. Netherlands Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 118. Netherlands Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 119. Netherlands Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 120. Netherlands Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 121. Netherlands Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 122. Rest of Europe Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 123. Rest of Europe Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 124. Rest of Europe Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 125. Rest of Europe Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 126. Rest of Europe Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 127. MEA Cancer Therapeutics and Biotherapeutics, by Country USD Million (2018-2023)
  • Table 128. MEA Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 129. MEA Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 130. MEA Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 131. MEA Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 132. MEA Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 133. Middle East Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 134. Middle East Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 135. Middle East Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 136. Middle East Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 137. Middle East Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 138. Africa Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 139. Africa Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 140. Africa Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 141. Africa Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 142. Africa Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 143. North America Cancer Therapeutics and Biotherapeutics, by Country USD Million (2018-2023)
  • Table 144. North America Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 145. North America Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 146. North America Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 147. North America Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 148. North America Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 149. United States Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 150. United States Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 151. United States Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 152. United States Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 153. United States Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 154. Canada Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 155. Canada Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 156. Canada Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 157. Canada Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 158. Canada Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 159. Mexico Cancer Therapeutics and Biotherapeutics, by Type USD Million (2018-2023)
  • Table 160. Mexico Cancer Therapeutics and Biotherapeutics, by Application USD Million (2018-2023)
  • Table 161. Mexico Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2018-2023)
  • Table 162. Mexico Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2018-2023)
  • Table 163. Mexico Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2018-2023)
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Company Basic Information, Sales Area and Its Competitors
  • Table 175. Cancer Therapeutics and Biotherapeutics: by Type(USD Million)
  • Table 176. Cancer Therapeutics and Biotherapeutics Chemotherapy , by Region USD Million (2025-2030)
  • Table 177. Cancer Therapeutics and Biotherapeutics Radiation Therapy , by Region USD Million (2025-2030)
  • Table 178. Cancer Therapeutics and Biotherapeutics Hormone Therapy , by Region USD Million (2025-2030)
  • Table 179. Cancer Therapeutics and Biotherapeutics Biotherapy , by Region USD Million (2025-2030)
  • Table 180. Cancer Therapeutics and Biotherapeutics: by Application(USD Million)
  • Table 181. Cancer Therapeutics and Biotherapeutics Household , by Region USD Million (2025-2030)
  • Table 182. Cancer Therapeutics and Biotherapeutics Hospital , by Region USD Million (2025-2030)
  • Table 183. Cancer Therapeutics and Biotherapeutics Others , by Region USD Million (2025-2030)
  • Table 184. Cancer Therapeutics and Biotherapeutics: by Therapy Type(USD Million)
  • Table 185. Cancer Therapeutics and Biotherapeutics Monoclonal Antibodies , by Region USD Million (2025-2030)
  • Table 186. Cancer Therapeutics and Biotherapeutics Vaccines , by Region USD Million (2025-2030)
  • Table 187. Cancer Therapeutics and Biotherapeutics Cell Therapy , by Region USD Million (2025-2030)
  • Table 188. Cancer Therapeutics and Biotherapeutics Gene Therapy , by Region USD Million (2025-2030)
  • Table 189. Cancer Therapeutics and Biotherapeutics Others , by Region USD Million (2025-2030)
  • Table 190. Cancer Therapeutics and Biotherapeutics: by Cancer Type(USD Million)
  • Table 191. Cancer Therapeutics and Biotherapeutics Blood Cancer , by Region USD Million (2025-2030)
  • Table 192. Cancer Therapeutics and Biotherapeutics Breast Cancer , by Region USD Million (2025-2030)
  • Table 193. Cancer Therapeutics and Biotherapeutics Lung Cancer , by Region USD Million (2025-2030)
  • Table 194. Cancer Therapeutics and Biotherapeutics Colorectal Cancer , by Region USD Million (2025-2030)
  • Table 195. Cancer Therapeutics and Biotherapeutics Prostate Cancer , by Region USD Million (2025-2030)
  • Table 196. Cancer Therapeutics and Biotherapeutics Others , by Region USD Million (2025-2030)
  • Table 197. Cancer Therapeutics and Biotherapeutics: by Treatment Drug(USD Million)
  • Table 198. Cancer Therapeutics and Biotherapeutics Nivolumab , by Region USD Million (2025-2030)
  • Table 199. Cancer Therapeutics and Biotherapeutics Ipilimumab , by Region USD Million (2025-2030)
  • Table 200. Cancer Therapeutics and Biotherapeutics Luspatercept , by Region USD Million (2025-2030)
  • Table 201. Cancer Therapeutics and Biotherapeutics Ramucirumab , by Region USD Million (2025-2030)
  • Table 202. Cancer Therapeutics and Biotherapeutics Others , by Region USD Million (2025-2030)
  • Table 203. South America Cancer Therapeutics and Biotherapeutics, by Country USD Million (2025-2030)
  • Table 204. South America Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 205. South America Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 206. South America Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 207. South America Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 208. South America Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 209. Brazil Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 210. Brazil Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 211. Brazil Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 212. Brazil Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 213. Brazil Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 214. Argentina Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 215. Argentina Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 216. Argentina Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 217. Argentina Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 218. Argentina Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 219. Rest of South America Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 220. Rest of South America Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 221. Rest of South America Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 222. Rest of South America Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 223. Rest of South America Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 224. Asia Pacific Cancer Therapeutics and Biotherapeutics, by Country USD Million (2025-2030)
  • Table 225. Asia Pacific Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 226. Asia Pacific Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 227. Asia Pacific Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 228. Asia Pacific Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 229. Asia Pacific Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 230. China Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 231. China Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 232. China Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 233. China Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 234. China Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 235. Japan Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 236. Japan Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 237. Japan Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 238. Japan Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 239. Japan Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 240. India Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 241. India Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 242. India Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 243. India Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 244. India Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 245. South Korea Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 246. South Korea Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 247. South Korea Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 248. South Korea Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 249. South Korea Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 250. Taiwan Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 251. Taiwan Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 252. Taiwan Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 253. Taiwan Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 254. Taiwan Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 255. Australia Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 256. Australia Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 257. Australia Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 258. Australia Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 259. Australia Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 260. Rest of Asia-Pacific Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 261. Rest of Asia-Pacific Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 262. Rest of Asia-Pacific Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 263. Rest of Asia-Pacific Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 264. Rest of Asia-Pacific Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 265. Europe Cancer Therapeutics and Biotherapeutics, by Country USD Million (2025-2030)
  • Table 266. Europe Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 267. Europe Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 268. Europe Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 269. Europe Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 270. Europe Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 271. Germany Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 272. Germany Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 273. Germany Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 274. Germany Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 275. Germany Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 276. France Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 277. France Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 278. France Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 279. France Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 280. France Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 281. Italy Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 282. Italy Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 283. Italy Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 284. Italy Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 285. Italy Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 286. United Kingdom Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 287. United Kingdom Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 288. United Kingdom Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 289. United Kingdom Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 290. United Kingdom Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 291. Netherlands Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 292. Netherlands Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 293. Netherlands Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 294. Netherlands Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 295. Netherlands Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 296. Rest of Europe Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 297. Rest of Europe Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 298. Rest of Europe Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 299. Rest of Europe Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 300. Rest of Europe Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 301. MEA Cancer Therapeutics and Biotherapeutics, by Country USD Million (2025-2030)
  • Table 302. MEA Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 303. MEA Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 304. MEA Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 305. MEA Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 306. MEA Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 307. Middle East Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 308. Middle East Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 309. Middle East Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 310. Middle East Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 311. Middle East Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 312. Africa Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 313. Africa Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 314. Africa Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 315. Africa Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 316. Africa Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 317. North America Cancer Therapeutics and Biotherapeutics, by Country USD Million (2025-2030)
  • Table 318. North America Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 319. North America Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 320. North America Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 321. North America Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 322. North America Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 323. United States Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 324. United States Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 325. United States Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 326. United States Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 327. United States Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 328. Canada Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 329. Canada Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 330. Canada Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 331. Canada Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 332. Canada Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 333. Mexico Cancer Therapeutics and Biotherapeutics, by Type USD Million (2025-2030)
  • Table 334. Mexico Cancer Therapeutics and Biotherapeutics, by Application USD Million (2025-2030)
  • Table 335. Mexico Cancer Therapeutics and Biotherapeutics, by Therapy Type USD Million (2025-2030)
  • Table 336. Mexico Cancer Therapeutics and Biotherapeutics, by Cancer Type USD Million (2025-2030)
  • Table 337. Mexico Cancer Therapeutics and Biotherapeutics, by Treatment Drug USD Million (2025-2030)
  • Table 338. Research Programs/Design for This Report
  • Table 339. Key Data Information from Secondary Sources
  • Table 340. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Therapeutics and Biotherapeutics: by Type USD Million (2018-2023)
  • Figure 5. Global Cancer Therapeutics and Biotherapeutics: by Application USD Million (2018-2023)
  • Figure 6. Global Cancer Therapeutics and Biotherapeutics: by Therapy Type USD Million (2018-2023)
  • Figure 7. Global Cancer Therapeutics and Biotherapeutics: by Cancer Type USD Million (2018-2023)
  • Figure 8. Global Cancer Therapeutics and Biotherapeutics: by Treatment Drug USD Million (2018-2023)
  • Figure 9. South America Cancer Therapeutics and Biotherapeutics Share (%), by Country
  • Figure 10. Asia Pacific Cancer Therapeutics and Biotherapeutics Share (%), by Country
  • Figure 11. Europe Cancer Therapeutics and Biotherapeutics Share (%), by Country
  • Figure 12. MEA Cancer Therapeutics and Biotherapeutics Share (%), by Country
  • Figure 13. North America Cancer Therapeutics and Biotherapeutics Share (%), by Country
  • Figure 14. Global Cancer Therapeutics and Biotherapeutics share by Players 2023 (%)
  • Figure 15. Global Cancer Therapeutics and Biotherapeutics share by Players (Top 3) 2023(%)
  • Figure 16. Global Cancer Therapeutics and Biotherapeutics share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 20. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 21. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 22. Eli Lilly & Company (United States) Revenue, Net Income and Gross profit
  • Figure 23. Eli Lilly & Company (United States) Revenue: by Geography 2023
  • Figure 24. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 25. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 26. Merck (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Merck (Germany) Revenue: by Geography 2023
  • Figure 28. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 30. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer (United States) Revenue: by Geography 2023
  • Figure 32. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Roche (Switzerland) Revenue: by Geography 2023
  • Figure 34. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 35. Sanofi (France) Revenue: by Geography 2023
  • Figure 36. Biogen IDEC (United States) Revenue, Net Income and Gross profit
  • Figure 37. Biogen IDEC (United States) Revenue: by Geography 2023
  • Figure 38. Genentech (United States) Revenue, Net Income and Gross profit
  • Figure 39. Genentech (United States) Revenue: by Geography 2023
  • Figure 40. Global Cancer Therapeutics and Biotherapeutics: by Type USD Million (2025-2030)
  • Figure 41. Global Cancer Therapeutics and Biotherapeutics: by Application USD Million (2025-2030)
  • Figure 42. Global Cancer Therapeutics and Biotherapeutics: by Therapy Type USD Million (2025-2030)
  • Figure 43. Global Cancer Therapeutics and Biotherapeutics: by Cancer Type USD Million (2025-2030)
  • Figure 44. Global Cancer Therapeutics and Biotherapeutics: by Treatment Drug USD Million (2025-2030)
  • Figure 45. South America Cancer Therapeutics and Biotherapeutics Share (%), by Country
  • Figure 46. Asia Pacific Cancer Therapeutics and Biotherapeutics Share (%), by Country
  • Figure 47. Europe Cancer Therapeutics and Biotherapeutics Share (%), by Country
  • Figure 48. MEA Cancer Therapeutics and Biotherapeutics Share (%), by Country
  • Figure 49. North America Cancer Therapeutics and Biotherapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • Bristol-Myers Squibb (United States)
  • Eli Lilly & Company (United States)
  • Johnson & Johnson (United States)
  • Merck (Germany)
  • Novartis (Switzerland)
  • Pfizer (United States)
  • Roche (Switzerland)
  • Sanofi (France)
  • Biogen IDEC (United States)
  • Genentech (United States)
Additional players considered in the study are as follows:
Amgen Inc. (United States) , Celgene Corporation (United States) , Others
Select User Access Type

Key Highlights of Report


Mar 2024 248 Pages 84 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Cancer Therapeutics and Biotherapeutics Quantitative research analysis
Cancer Therapeutics and Biotherapeutics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AstraZeneca (United Kingdom), Bristol-Myers Squibb (United States), Eli Lilly & Company (United States), Johnson & Johnson (United States), Merck (Germany), Novartis (Switzerland), Pfizer (United States), Roche (Switzerland), Sanofi (France), Biogen IDEC (United States) and Genentech (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"The increasing focus on targeted therapies and precision medicine." is seen as one of major influencing trends for Cancer Therapeutics and Biotherapeutics Market during projected period 2023-2030.
The Cancer Therapeutics and Biotherapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Cancer Therapeutics and Biotherapeutics Report?

Have a Query? Click Here

Other Related Reports

Anti-Aging Products and Therapies Comprehensive Study by Type (Human Growth Hormone, Stem Cell, Placenta, Botulinum Toxin, Hyaluronic Acid), Application (Anti-Pigmentation Therapy, Anti-Cellulite Tre...
$ 3750
Duchenne Muscular Dystrophy Comprehensive Study by Type (Duchenne/Becker (DMD/BMD), Myotonic (DM), Limb-Girdle (LGMD), Facioscapulohumeral (FSHD), Congenital (CMD), Oculopharyngeal (OPMD), Emery-Drei...
$ 3650
Diabetic Neuropathy Comprehensive Study by Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), Application (Hospitals, Clinics, Retail Pharmacy, Online Pharmacy...
$ 3750
Donepezil Comprehensive Study by Type (5mg, 10mg, 23mg), Application (Hospitals, Clinics, Drugstore), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2027
$ 3500
Leukemia Therapeutics Comprehensive Study by Type (Chemotherapy, Biological Therapy, Radiation therapy, Targeted therapy), Application (Hospital, Clinic), Mode of Administration (Oral, Injectable), M...
$ 3750
Age Related Macular Degeneration Comprehensive Study by Type (Wet AMD, Dry AMD), Drugs (Lucentis, Eylea, Avastin, Others), Route of Administration (Intravenous, Intravitreal) Players and Region - Glo...
$ 3500